STOCK TITAN

[Form 4] KALA BIO, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

KALA BIO (KALA) reported an insider transaction by its Chief Business Officer. On 10/22/2025, the officer sold 20,806 shares of common stock at a $0.83 weighted average price, with trades ranging from $0.82 to $0.84. Following the sale, the officer beneficially owned 41,760 shares directly.

The reported balance includes 28,878 unvested RSUs, which are awards that may settle in shares as they vest. The filing lists direct ownership and does not indicate joint or group filing.

KALA BIO (KALA) ha riferito una transazione interna da parte del proprio Chief Business Officer. Il 22/10/2025, l'ufficiale ha venduto 20.806 azioni ordinarie a un prezzo medio ponderato di $0,83, con operazioni che vanno da $0,82 a $0,84. A seguito della vendita, l'ufficiale possedeva direttamente 41.760 azioni.

Il saldo riportato include 28.878 RSU non vestite, che sono premi che possono essere regolarmente liquidati in azioni man mano che vestono. La dichiarazione riporta la proprietà diretta e non indica una dichiarazione congiunta o di gruppo.

KALA BIO (KALA) informó una transacción interna por parte de su Director de Negocios. El 22/10/2025, el directivo vendió 20,806 acciones de acciones comunes a un precio medio ponderado de $0,83, con operaciones que oscilaban entre $0,82 y $0,84. Después de la venta, el directivo poseía directamente 41,760 acciones.

El saldo reportado incluye 28,878 RSU no vestidas, que son premios que pueden liquidarse en acciones a medida que vestigen. La presentación indica propiedad directa y no señala presentación conjunta o grupal.

KALA BIO (KALA) 최고 사업 책임자의 내부자 거래를 보고했습니다. 2025/10/22에 임원은 공통 주식 20,806주를 가중평균가 $0.83로 매도했으며, 체결가는 $0.82에서 $0.84 사이였습니다. 매도 후 임원은 직접적으로 41,760주의 주식을 보유하게 되었습니다.

보고된 잔액은 승인되지 않은 28,878 RSU를 포함하는데, 이는 vesting될 때 주식으로 결산될 수 있는 보상입니다. 공시는 직접 보유를 나타내며 공동 보유 또는 그룹 보유를 나타내지 않습니다.

KALA BIO (KALA) a signalé une transaction interne par son Directeur Commercial. Le 22/10/2025, le cadre a vendu 20 806 actions ordinaires à un prix moyen pondéré de $0,83, des transactions allant de $0,82 à $0,84. Suite à la vente, le cadre possédait directement 41 760 actions.

Le solde déclaré inclut 28 878 RSU non vesties, qui sont des récompenses pouvant être réglées en actions au fur et à mesure qu'elles se vestent. Le dépôt indique une détention directe et n’indique pas de dépôt conjoint ou groupé.

KALA BIO (KALA) meldete eine Insider-Transaktion durch seinen Chief Business Officer. Am 22.10.2025 hat der Beauftragte 20.806 Aktien Stammaktien zu einem gewichteten Durchschnittspreis von $0,83 verkauft, wobei die Trades zwischen $0,82 und $0,84 lagen. Nach dem Verkauf besaß der Beauftragte direkt 41.760 Aktien.

Der gemeldete Saldo umfasst 28.878 unvestete RSU, bei denen es sich um Vergütungen handelt, die sich beim Vesting in Aktien auflösen können. Die Einreichung weist auf Direktbesitz hin und gibt keine gemeinsame oder Gruppeneinreichung an.

KALA BIO (KALA) أبلغت عن صفقة داخلية من قبل مدير الأعمال التنفيذي لديها. في 2025/10/22، باع المسؤول ما تبقّى من 20,806 سهمًا من الأسهم العادية بسعر متوسط مرجّح قدره $0.83، وكانت الصفقات تتراوح بين $0.82 و $0.84. عقب البيع، امتلك المسؤول 41,760 سهمًا مباشرةً.

الرصيد المبلغ عنه يشمل 28,878 RSU غير vesting، وهي جوائز قد تسوى في أسهم مع vesting. تُظهر المذكرة الملكية المباشرة ولا تشير إلى تقديم مشترك أو جماعي.

Positive
  • None.
Negative
  • None.

KALA BIO (KALA) ha riferito una transazione interna da parte del proprio Chief Business Officer. Il 22/10/2025, l'ufficiale ha venduto 20.806 azioni ordinarie a un prezzo medio ponderato di $0,83, con operazioni che vanno da $0,82 a $0,84. A seguito della vendita, l'ufficiale possedeva direttamente 41.760 azioni.

Il saldo riportato include 28.878 RSU non vestite, che sono premi che possono essere regolarmente liquidati in azioni man mano che vestono. La dichiarazione riporta la proprietà diretta e non indica una dichiarazione congiunta o di gruppo.

KALA BIO (KALA) informó una transacción interna por parte de su Director de Negocios. El 22/10/2025, el directivo vendió 20,806 acciones de acciones comunes a un precio medio ponderado de $0,83, con operaciones que oscilaban entre $0,82 y $0,84. Después de la venta, el directivo poseía directamente 41,760 acciones.

El saldo reportado incluye 28,878 RSU no vestidas, que son premios que pueden liquidarse en acciones a medida que vestigen. La presentación indica propiedad directa y no señala presentación conjunta o grupal.

KALA BIO (KALA) 최고 사업 책임자의 내부자 거래를 보고했습니다. 2025/10/22에 임원은 공통 주식 20,806주를 가중평균가 $0.83로 매도했으며, 체결가는 $0.82에서 $0.84 사이였습니다. 매도 후 임원은 직접적으로 41,760주의 주식을 보유하게 되었습니다.

보고된 잔액은 승인되지 않은 28,878 RSU를 포함하는데, 이는 vesting될 때 주식으로 결산될 수 있는 보상입니다. 공시는 직접 보유를 나타내며 공동 보유 또는 그룹 보유를 나타내지 않습니다.

KALA BIO (KALA) a signalé une transaction interne par son Directeur Commercial. Le 22/10/2025, le cadre a vendu 20 806 actions ordinaires à un prix moyen pondéré de $0,83, des transactions allant de $0,82 à $0,84. Suite à la vente, le cadre possédait directement 41 760 actions.

Le solde déclaré inclut 28 878 RSU non vesties, qui sont des récompenses pouvant être réglées en actions au fur et à mesure qu'elles se vestent. Le dépôt indique une détention directe et n’indique pas de dépôt conjoint ou groupé.

KALA BIO (KALA) meldete eine Insider-Transaktion durch seinen Chief Business Officer. Am 22.10.2025 hat der Beauftragte 20.806 Aktien Stammaktien zu einem gewichteten Durchschnittspreis von $0,83 verkauft, wobei die Trades zwischen $0,82 und $0,84 lagen. Nach dem Verkauf besaß der Beauftragte direkt 41.760 Aktien.

Der gemeldete Saldo umfasst 28.878 unvestete RSU, bei denen es sich um Vergütungen handelt, die sich beim Vesting in Aktien auflösen können. Die Einreichung weist auf Direktbesitz hin und gibt keine gemeinsame oder Gruppeneinreichung an.

KALA BIO (KALA) أبلغت عن صفقة داخلية من قبل مدير الأعمال التنفيذي لديها. في 2025/10/22، باع المسؤول ما تبقّى من 20,806 سهمًا من الأسهم العادية بسعر متوسط مرجّح قدره $0.83، وكانت الصفقات تتراوح بين $0.82 و $0.84. عقب البيع، امتلك المسؤول 41,760 سهمًا مباشرةً.

الرصيد المبلغ عنه يشمل 28,878 RSU غير vesting، وهي جوائز قد تسوى في أسهم مع vesting. تُظهر المذكرة الملكية المباشرة ولا تشير إلى تقديم مشترك أو جماعي.

KALA BIO (KALA) 报告其首席商务官的内部交易。在 2025/10/22,该官员 出售了20,806股普通股,按加权平均价格 $0.83,交易区间为 $0.82 至 $0.84。出售后,该官员直接< b>拥有41,760股。

报告的余额 包括28,878股未归属的RSU,这是在 vest 时可能以股票结算的奖励。此披露列出直接所有权,并未指示联合或集团申报。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kharabi Darius

(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF BUSINESS OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 S 20,806 D $0.83(1) 41,760(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. Includes 28,878 unvested RSUs.
/s/ Mary Reumuth, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KALA (KALA) disclose in this Form 4?

The Chief Business Officer sold 20,806 shares on 10/22/2025 at a $0.83 weighted average price.

What price range were the KALA shares sold at?

Sales occurred between $0.82 and $0.84, inclusive, with a weighted average of $0.83.

How many KALA shares does the insider own after the transaction?

The officer beneficially owns 41,760 shares directly after the reported sale.

Does the remaining KALA ownership include equity awards?

Yes. The balance includes 28,878 unvested RSUs.

What is the insider’s role at KALA BIO?

The reporting person is an officer, serving as Chief Business Officer.

Was this a single trade or multiple trades?

Multiple trades were executed within the $0.82–$0.84 range; the reported price is a weighted average.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

5.31M
6.06M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON